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Summary statement 22 
A novel genetic mouse model of sporadic Beckwith-Wiedemann syndrome 23 
recapitulates placentomegaly but late gestation fetal growth restriction contrasts with 24 
fetal overgrowth characteristic of BWS.  25 
 26 
Abstract 27 
Beckwith-Wiedemann syndrome (BWS) is a complex imprinting disorder involving 28 
fetal overgrowth and placentomegaly and associated with a variety of genetic and 29 
epigenetic mutations affecting expression of imprinted genes on human 30 
chromosome 11p15.5. Most BWS cases are linked to loss of methylation at the 31 
Imprint Control Region 2 (ICR2) within this domain, which in mice regulates the 32 
silencing of several maternally expressed imprinted genes. Modelling this disorder in 33 
mice is confounded by the unique embryonic requirement for Ascl2 which is 34 
imprinted in mice but not humans. To overcome this issue, we generated a novel 35 
model combining a truncation of distal chromosome 7 allele (DelTel7) with 36 
transgenic rescue of Ascl2 expression. This novel model recapitulated 37 
placentomegaly associated with BWS but did not lead to fetal overgrowth. 38 
 39 
40 
 3
Introduction 41 
Beckwith-Wiedemann syndrome (BWS; MIM #130650) is a complex imprinting 42 
disorder associated with a range of growth and developmental phenotypes, including 43 
overgrowth, macroglossia, abdominal wall defects and an increased frequency of 44 
childhood tumours (Brioude et al., 2018; Lapunzina, 2005; Weksberg et al., 2010) 45 
Historically, BWS has been diagnosed in the presence of three or more “major” 46 
criteria, including: abdominal wall defects, macroglossia (enlarged tongue), 47 
macrosomia (birth weight >97th percentile), ear creases/pits and visceromegaly 48 
(enlarged abdominal organs). BWS may also be diagnosed on presentation with two 49 
major criteria and at least one “minor” criterion, including placental defects, 50 
placentomegaly, neonatal hypoglycaemia and cardiomegaly (Ounap, 2016; 51 
Weksberg et al., 2010). However, a recent Consensus Statement proposes a re-52 
evaluation of diagnostic criteria, describing several cardinal features (including 53 
macroglossia, lateralised overgrowth and placental mesenchymal dysplasia) 54 
alongside additional suggestive features (including placentomegaly and fetal 55 
overgrowth) (Brioude et al., 2018). The prevalence of BWS is estimated at 1 in 56 
13,700 live births (Thorburn et al., 1970). The majority of cases occur sporadically, 57 
while approximately 15% are inherited, for instance via loss of a functional maternal 58 
CDKN1C allele (Weksberg et al., 2010; Weksberg et al., 2005; Weksberg et al., 59 
2003). 60 
BWS is caused by genetic or epigenetic mutations that disrupt expression of 61 
one or more imprinted genes, which, unlike most autosomal genes, are expressed 62 
predominantly from one parental allele (Ferguson-Smith and Surani, 2001). The 63 
parent-of-origin-specific expression of imprinted genes is regulated through 64 
mechanisms that include differential methylation and expression of long non-coding 65 
RNAs (Delaval and Feil, 2004; Koerner et al., 2009; O'Neill, 2005). Over 100 66 
imprinted genes have been identified in mice, with around half of these known to be 67 
also imprinted in humans (Ishida and Moore, 2013). Most imprinted genes have 68 
critical roles in regulating fetal and/or placental growth (Cleaton et al., 2014; Tunster 69 
et al., 2013), with the parental conflict hypothesis predicting that paternally 70 
expressed imprinted genes promote growth and maternally expressed imprinted 71 
genes restrict growth (Moore and Haig, 1991). 72 
BWS results from genetic or epigenetic defects within a ~1 Mb imprinted 73 
region of human chromosome 11p15.5 (Koufos et al., 1989; Ping et al., 1989). 74 
Imprinting of genes within this domain is associated with differential methylation of 75 
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two imprinting control regions; IC1 and IC2 (also known as ICR1 and ICR2) (Du et 76 
al., 2003; Du et al., 2004). Methylation of the paternal ICR1 suppresses the non-77 
coding H19 RNA whilst permitting expression of the growth-enhancing IGF2. On the 78 
maternal chromosome, absence of ICR1 DNA methylation is associated with 79 
expression of H19 and suppression of IGF2 (reviewed in Ideraabdullah et al., 2008). 80 
In contrast, maternal methylation of ICR2 prevents transcription of the long non-81 
coding RNA KCNQ1OT1, which is predicted to permit the expression of several 82 
genes, including the growth-limiting CDKN1C and PHLDA2. On the paternal 83 
chromosome, absence of ICR2 methylation permits transcription of KCNQ1OT1 and 84 
is associated with silencing in cis of the imprinted genes in the region (Du et al., 85 
2004). Several genetic and epigenetic defects have been associated with BWS, 86 
including: paternal uniparental disomy (pUPD), gain of ICR1 methylation, loss of 87 
ICR2 methylation and mutations within the CDKN1C coding region (Weksberg et al., 88 
2010; Weksberg et al., 2005; Weksberg et al., 2003). Whilst maternally inherited 89 
CDKN1C mutations account for nearly half of familial cases, only ~5% of sporadic 90 
cases are associated with such mutations (Lam et al., 1999; Lee et al., 1997). 91 
Instead, the majority of sporadic cases are attributable to loss of ICR2 methylation, 92 
which effectively silences expression of several maternally expressed genes 93 
regulated by KCNQ1OT1, including CDKN1C and PHLDA2 (Gaston et al., 2001; Lee 94 
et al., 1999; Smilinich et al., 1999).  95 
Human 11p15.5 is syntenic with mouse distal chromosome 7, with the 96 
exception that in humans ICR1 is located towards the telomere and ICR2 towards 97 
the centromere, whereas in the mouse this orientation is reversed. Despite 98 
conservation of the BWS region between species, modelling BWS in mice remains a 99 
complex undertaking. Loss of function of CDKN1C, seen most often in familial BWS, 100 
has been modelled by the generation of three independent Cdkn1c mutant alleles 101 
which recapitulate some aspects of the disorder (Takahashi et al., 2000; Yan et al., 102 
1997; Zhang et al., 1997). However, these models are of limited relevance as BWS 103 
is typically sporadic and predominantly associated with loss of methylation at ICR2, 104 
which is predicted to lead to the silencing of all the maternally expressed genes 105 
within the domain.  106 
The generation of a mouse model possessing a truncation of distal 107 
chromosome 7 (DelTel7) provided an important first step towards creating a 108 
mechanistic model of loss of expression of imprinted genes associated with loss of 109 
ICR2 methylation in human (Oh et al., 2008). The DelTel7 truncation encompasses 110 
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the entire ICR2 imprinted domain and an additional ~20 non-imprinted genes located 111 
at the telomeric end of mouse distal chromosome 7, but with imprinted expression of 112 
the ICR1 maintained (Fig. 1). Paternal inheritance of the ~2.6 Mb DelTel7 deletion 113 
allele caused no adverse phenotype, consistent with the paternally silenced status of 114 
protein coding genes within the domain as well as absence of haploinsufficiency 115 
effects. However, maternal inheritance of the deletion resulted in embryonic lethality 116 
by E10.5 (Oh et al., 2008). Placentae of maternal DelTel7 heterozygotes were 117 
characterised by a loss of junctional zone and expanded giant cell layer, a 118 
phenotype reminiscent of Ascl2 loss of function (Guillemot et al., 1994; Oh et al., 119 
2008). Indeed, reactivation of the paternal IC2 domain by paternal transmission of an 120 
IC2 KO allele (KvDMR1 KO) was sufficient to rescue embryonic lethality and restore 121 
placental structure, thus attributing the lethality and placental defects to loss of 122 
expression of one or more genes within the IC2 domain (Oh-McGinnis et al., 2010).  123 
A key difference in imprinting between human and mouse in the BWS region 124 
is the status of Ascl2/ASCL2, which in mice is maternally expressed, but escapes 125 
imprinting in humans (Miyamoto et al., 2002; Monk et al., 2006). The biallelic 126 
expression of ASCL2 in humans may explain survival of human conceptuses with 127 
ICR2 hypomethylation, with ASCL2 expression maintained from the active paternal 128 
allele, whereas loss of IC2 imprinting in the mouse completely ablates Ascl2 129 
expression. We recently reported the generation of a transgenic mouse carrying a 130 
BAC transgene spanning the Ascl2 gene (Ascl2BAC) (Reed et al., 2012; Tunster et 131 
al., 2016). Here, we asked whether transgenic Ascl2 expression could rescue the 132 
embryonic lethality in the context of maternal DelTel7 inheritance, to allow a later 133 
characterisation of this model. 134 
 135 
Results  136 
Restoring Ascl2 expression rescues DelTel7 lethality  137 
We first explored whether restoring Ascl2 gene expression could rescue the 138 
embryonic lethality associated with deletion of the maternal IC2 domain by mating 139 
hemizygous males carrying Ascl2BAC with heterozygous females that inherited the 140 
DelTel7 allele from their father. Full rescue should result in viability beyond E10.5 of 141 
three genotypes in equal proportions: fully wild-type embryos inheriting neither 142 
genetic alteration; Ascl2BAC embryos inheriting only the transgene from their father; 143 
and DelTel7; Ascl2BAC double mutants (called DelTel7BAC) inheriting the DelTel7 144 
allele from their mother and Ascl2BAC from their father. DelTel7 embryos inheriting 
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only the deletion allele should not be observed beyond ~E10.5 (Oh et al., 2008). 146 
Twenty-two litters were analysed at E14.5, comprising a total of 158 viable 147 
conceptuses of which 35 were DelTel7BAC (Table 1) and twenty-six litters were 148 
analysed at E18.5 comprising 147 viable conceptuses of which 30 were DelTel7BAC 149 
(Table 1). The presence of the transgene successfully, although not completely, 150 
rescued lethality imposed by loss of function of the maternally expressed genes 151 
within the IC2 domain allowing a phenotypic assessment of the rescued 152 
conceptuses. 153 
 154 
Placentomegaly and fetal growth restriction of DelTel7BAC conceptuses 155 
Two diagnostic characteristics of BWS are fetal overgrowth and placentomegaly at 156 
term. Consistent with this, DelTel7BAC placentae (P) were significantly heavier than 157 
those of control littermates at both E14.5 (114%; p = 6.26 x 10-10) and E18.5 (130%; 158 
p = 1.16 x 10-14) (Fig. 2A). However, whilst there was no difference in fetal (F) 159 
weights at E14.5, DelTel7BAC fetuses were significantly lighter than controls at E18.5 160 
(88%; p = 2.13 x 10-9) (Fig. 2B). Consequently, the F:P ratio, an approximation of 161 
placental efficiency (Fowden et al., 2009), was significantly reduced at both E14.5 162 
(89%; p = 0.0167) and E18.5 (68%; p = 3.95 x 10-22) (Fig. 2C).  163 
 164 
Progressive loss of junctional zone in DelTel7BAC placentae 165 
Growth restriction of DelTel7BAC fetuses occurred late in gestation typically indicative 166 
of an extrinsic cause, such as placental insufficiency. To further investigate this 167 
possibility, we undertook a detailed characterisation of DelTel7BAC placentae. The 168 
mature mouse placenta comprises three structurally and functionally distinct layers. 169 
The maternal decidua (Dec) forms from uterine cells in response to implantation, the 170 
endocrine junctional zone (Jz) is responsible for synthesis and secretion of signalling 171 
factors, and the labyrinth zone (Lz) is responsible for nutrient and gas transfer 172 
(Watson and Cross, 2005). H&E staining of placental midline sections revealed a 173 
breakdown in the boundary of the Jz with both the Lz and Dec at E14.5 and E18.5 174 
(Fig. 3A, B). The Jz is primarily comprised of glycogen trophoblast cells (GlyT) and 175 
the endocrine spongiotrophoblast (SpT). Periodic acid Schiff staining, which stains 176 
GlyT, demonstrated a mislocalisation and increased migration of glycogen cells to 177 
the decidua at E14.5, although no overt difference in staining was observed at E18.5 178 
(Fig. 3C, D). In situ hybridisation with a riboprobe for the Jz marker Tpbpa further 179 
demonstrated the loss of Jz integrity at E14.5 and revealed a substantial loss of Jz 180 
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staining at E18.5 (Fig. 3E, F). Biochemical quantitation of placental glycogen stores 181 
at E14.5 identified a modest 27% increase in total placental glycogen (p = 2.61 x 10-182 
3), but this was normalised at E18.5 (Fig. 4A). When adjusted for placental weight, 183 
DelTel7BAC placentae did not accumulate significantly more glycogen per gram of 184 
placenta at either stage (Fig. 4B). 185 
 186 
Altered gene expression in DelTel7BAC placentae 187 
The mature mouse placenta comprises at least nine distinct trophoblast sub-types 188 
(Gasperowicz et al., 2013; John and Hemberger, 2012), each of which is 189 
characterised by a unique gene expression profile and spatial organisation. 190 
Expression analysis of cell-type-specific gene markers facilitates an assessment of 191 
the relative contribution of the various trophoblast lineages to the placenta. 192 
Consistent with the gross histological assessment of placental structure (Fig. 3), 193 
expression of the Jz marker Tpbpa was reduced to 41% of wild type levels at E18.5, 194 
with a similar trend observed at E14.5 (64%), although without achieving statistical 195 
significance (p = 0.0557) (Fig. 5A). Expression of Flt1, which is predominantly 196 
expressed in the Jz, was reduced to 46% and 56% of wild type levels at E14.5 and 197 
E18.5 respectively (Fig. 5A). Expression of genes that are specifically (Prl8a8) or 198 
predominantly (Psg17, Psg18, Psg19, Psg21) expressed in the SpT was 199 
substantially diminished at both E14.5 and E18.5, with expression ranging between 200 
21% and 45% of wild type levels (Fig. 5A). In contrast, genes expressed either 201 
specifically or predominantly in GlyT were either elevated or unaltered in DelTel7BAC 202 
placentae. Expression of Pcdh12, an early marker of GlyT, was increased 84% at 203 
E14.5, with a similar trend at E18.5, whereas Gjb3, a marker of mature glycogen 204 
cells (Coan et al., 2006), was unaltered at both E14.5 and E18.5. Expression of 205 
Prl7b1, a marker of migratory GlyT (Simmons et al., 2008b), was elevated 2-fold at 206 
E14.5, consistent with the pattern of PAS staining previously described (Fig. 3B). 207 
Prl6a1, a marker of non-migratory GlyT (Simmons et al., 2008b), exhibited a trend 208 
for increased expression at E14.5, although without achieving statistical significance, 209 
with unaltered expression at E18.5 (Fig. 5A). The reduced expression of Jz markers 210 
in DelTel7BAC placentas is consistent the Cdkn1c-/+ placenta, in which Tpbpa, Prl8a8 211 
and Flt1 were all downregulated at E15.5 (Tunster et al., 2011). 212 
 The boundary between the Jz and Dec is marked by a discontinuous layer of 213 
Parietal Trophoblast Giant Cells (P-TGC). An additional four Trophoblast Giant Cell 214 
(TGC) sub-types have been described, with spiral artery TGCs (SpA-TGCs) lining 215 
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maternal spiral arteries as they enter the implantation site, canal-TGCs (C-TGCs) 216 
lining maternal blood canals that traverse the Jz and Lz, and sinusoidal TGCs (S-217 
TGCs) replacing the endothelial lining of maternal blood sinuses in the Lz (Simmons 218 
et al., 2007). Finally, the recently described channel TGCs (Ch-TGC) line venous 219 
channels that traverse the Jz carrying blood away from the placenta (Gasperowicz et 220 
al., 2013). Expression of Prl3b1, which is expressed in SpT in addition to P-, C-, S- 221 
and Ch-TGCs, was reduced to 45% of wild type levels at E14.5, but not significantly 222 
altered at E18.5 (Fig 5B). Hand1, which is expressed in at least four TGC lineages 223 
(Simmons et al., 2007) (expression in Ch-TGCs has not been investigated) was 224 
unaltered at both E14.5 and E18.5. Expression of Ctsq, which is expressed in S-225 
TGCs and Ch-TGCs (Gasperowicz et al., 2013; Simmons et al., 2007), was 226 
expressed at 50% of wild type levels at E14.5, although without reaching statistical 227 
significance (p = 0.140), with expression normalised by E18.5 (Fig. 5B). Prl2c, which 228 
is expressed in SpT in addition to P-, SpA-, C-, and Ch-TGCs, was expressed at 229 
67% of wild type levels at E14.5 but was unaltered at E18.5 (Fig. 5B). Taken 230 
together, these gene expression data are indicative of an early loss of the endocrine 231 
SpT population that persists to term, with a transient increase in GlyT at mid-232 
gestation that is normalised by term. 233 
 234 
Elevated expression of syncytiotrophoblast markers 235 
Trophoblast cells in the Lz are arranged in a trilaminar structure, with a layer of S-236 
TGCs replacing maternal endothelial cells, adjacent to which is a bilayer of 237 
multinucleated syncytiotrophoblast cells (SynT-I and SynT-II) formed by cell fusion. 238 
The endothelial lining of fetal vessels remains intact and lies adjacent to SynT-II 239 
(Rossant and Cross, 2001; Simmons and Cross, 2005; Simmons et al., 2008a). 240 
Expression of Flk1, which is expressed in fetal endothelium (Hirashima et al., 2003), 241 
was reduced to 71% of normal levels at E14.5, but was unaltered at E18.5. 242 
Expression of Dlx3, which is widely expressed in all Lz trophoblast (Simmons et al., 243 
2008a), was unaltered at both stages. Syna and Ly6e, which are expressed 244 
predominantly in SynT-I (Hughes et al., 2013; Simmons et al., 2008a), were 245 
unaltered at E14.5, with an 80% increase in Syna expression at E18.5, whilst Ly6e 246 
expression remained unaltered at this stage (Fig. 5C). Expression of Gcm1 and 247 
Synb, both markers of SynT-II (Simmons et al., 2008a), were unaltered at E14.5, but 248 
were elevated ~10-fold and ~3-fold at E18.5 respectively (Fig. 5D). DelTel7BAC 249 
placentae were therefore characterised by defects in both fetal-derived placental 250 
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regions. 251 
 252 
Excluding a role for elevated Ascl2 253 
In our initial work with Ascl2BAC we reported that Ascl2 was expressed at 2.7-fold 254 
endogenous levels in the small intestine (Reed et al., 2012), but more recently we 255 
reported that placental expression exceeds by 6-fold the endogenous levels (Tunster 256 
et al., 2016). Thus, a potential shortcoming of this model is the concomitant over-257 
expression of Ascl2 in the context of loss of expression of the IC2 domain genes. 258 
However, we have also demonstrated that the placental defects associated with 259 
elevated Ascl2 was dependent upon Phlda2, with Ascl2 unable to restrict the SpT on 260 
a Phlda2 null background (Tunster et al., 2016). We therefore hypothesised that 261 
excess Ascl2 would have no phenotypic consequence in the context of maternal 262 
inheritance of the DelTel7 deletion allele, in which expression of Phlda2 is ablated. 263 
To further explore this hypothesis, we investigated the phenotypic outcomes 264 
associated with Ascl2BAC combined with loss of function of either Phlda2 or Cdkn1c 265 
in isolation. 266 
Transgenic Ascl2BAC males were mated with females carrying either a Phlda2 267 
or Cdkn1c loss-of-function allele. Twenty-six litters were generated from crossing the 268 
Phlda2 null line with Ascl2BAC males, comprising 187 viable conceptuses and twenty 269 
litters were generated from crossing the Cdkn1c null line with Ascl2BAC males, 270 
comprising 150 viable conceptuses. All genotypes were recovered at the expected 271 
frequency at E18.5 (Table 2). 272 
Consistent with previous reports (Frank et al., 2002; Tunster et al., 2015; 273 
Tunster et al., 2011), both Phlda2-/+ (122%; p = 6.73 x 10-12) and Cdkn1c-/+ (136%; p 274 
= 1.00 x 10-20) placentae were significantly heavier than control littermates. Similarly, 275 
both Phlda2-/+BAC (134%; p = 1.00 x 10-16) and Cdkn1c-/+BAC (130%; p = 6.66 x 10-16) 276 
placentae were significantly heavier than those of control littermates (Fig. 6A, B). 277 
Whilst Phlda2-/+BAC placentae were heavier than Phlda2-/+ (110%; p = 1.82 x 10-4), 278 
there was no difference in placental weight between Cdkn1c-/+ and Cdkn1c-/+BAC 279 
(96%; p = 0.0946) (Fig 6A, B). Importantly, fetal weights of Phlda2-/+ (102%; p = 280 
0.604) and Phlda2-/+BAC (96%; p = 0.0752) did not differ significantly from that of 281 
control littermates, although Phlda2-/+BAC fetuses were slightly lighter than Phlda2-/+ 282 
(94%; p = 0.00416) (Fig. 6C). We previously reported that Cdkn1c-/+ embryos on a 283 
129 genetic background were 15% heavier than control littermates at E15.5 and 8% 284 
heavier at E18.5, with this slowdown in fetal growth trajectory late in gestation 285 
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attributable to the associated placental defects (Tunster et al., 2011). On this 129 x 286 
CD1 genetic background, Cdkn1c-/+ embryos were 14% heavier than control 287 
littermates at E18.5 (p = 6.21 x 10-6), with Cdkn1c-/+BAC 9% heavier than control (p = 288 
0.0232), although fetal weight did not differ significantly between Cdkn1c-/+ and 289 
Cdkn1c-/+BAC (95%; p = 0.155) (Fig 6D). F:P ratios were significantly reduced for all 290 
genotypes as a result of substantial placentomegaly (with the exception of Ascl2BAC) 291 
(Fig. 6E, F). 292 
Similarly, Ascl2BAC did not overtly affect placental phenotype in the context of 293 
loss of function of Phlda2 or Cdkn1c. For instance, the increased placental glycogen 294 
associated with loss of Phlda2 was not influenced by the presence of Ascl2BAC (Fig 295 
6G), and whilst both Cdkn1c-/+ and Cdkn1c-/+BAC placentas exhibited a trend for 296 
reduced placental glycogen, this did not achieve statistical significance (Fig 6H). Key 297 
lineage markers were typically expressed at normal levels in Phlda2-/+BAC placentas, 298 
whilst the expression profile of Cdkn1c-/+BAC placentas was largely consistent with 299 
previous reports of Cdkn1c-/+ placentas (Tunster et al., 2011). Importantly, consistent 300 
with DelTel7BAC placenta, expression of the SynT-I marker Syna and the SynT-II 301 
marker Synb was upregulated in Cdkn1c-/+BAC placentas, although upregulation of 302 
Synb was less severe (2.5 fold vs 10 fold respectively), consistent with the more 303 
severe DelTel7BAC phenotype resulting from the combined loss of Cdkn1c and 304 
Phlda2.  305 
Taken together, these data support the conclusion that Ascl2BAC does not 306 
contribute significantly to FGR in the context of loss of function of Cdkn1c or Phlda2 307 
in isolation, with no adverse effect on Phlda2-/+BAC fetal growth and Cdkn1c-/+BAC 308 
fetuses retaining the overgrowth inferred by loss of function of Cdkn1c. 309 
 310 
Discussion 311 
This work sought to establish a novel genetic model of sporadic Beckwith-312 
Wiedemann syndrome associated with loss of maternally-expressed genes in the 313 
ICR2 imprinted domain. Loss of expression of the IC2 domain imprinted genes was 314 
modelled by maternal inheritance of the DelTel7 truncation allele, with co-inheritance 315 
of Ascl2BAC to rescue the embryonic lethality caused by loss of Ascl2 in the mouse. 316 
Whilst placentomegaly of DelTel7BAC conceptuses was consistent with BWS, we did 317 
not recapitulate fetal overgrowth, which was previously considered a defining 318 
characteristic of BWS (Brioude et al., 2018; Weksberg et al., 2010). Our findings 319 
share some similarity with our previous characterisation of the Cdkn1c-/+ model of 320 
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familial BWS. Cdkn1c-/+ placentae were substantially heavier than controls with a 321 
diminished Jz. Whilst fetal overgrowth was apparent at E15.5 and E18.5, this was 322 
absent at birth.  The Lz of Cdkn1c-/+ placentae was characterised by large thrombotic 323 
lesions, which we reasoned compromised placental function, leading to the loss of 324 
fetal overgrowth during late gestation (Tunster et al., 2011). Similarly, whilst 325 
DelTel7BAC placentae were substantially heavier than control placentae, we did not 326 
observe fetal overgrowth at either E14.5 or E18.5. Whilst we did not observe the 327 
large thrombotic lesions of Cdkn1c-/+ placentae, the substantially elevated expression 328 
of the SynT-II markers Gcm1 and Synb is consistent with a widespread disruption of 329 
the trilaminar structure of the Lz. We conclude that the larger placenta associated 330 
with both BWS models is unable to support fetal overgrowth as a consequence of 331 
severe placental defects that compromise normal placental function. Our data is 332 
consistent with loss of function of the maternally expressed genes within the IC2 333 
domain having a more profound consequence for fetal growth potentially due to the 334 
tighter epigenetic regulation of these genes in mice relative to the human locus.  335 
 We previously reported that early fetal overgrowth in the Cdkn1c-/+ model of 336 
familial BWS was lost towards term (Tunster et al., 2011). We suggested that this 337 
could be due to severe placental defects that impair the ability of Cdkn1c-/+ fetuses to 338 
compete for shared maternal resources. Alternatively, given the role of Phlda2 in 339 
regulating placental glycogen stores (Tunster et al., 2010), thought to be important 340 
for fetal growth (Coan et al., 2006), we hypothesised that a combined loss of function 341 
of the two genes might be required for fetal overgrowth to manifest (Tunster et al., 342 
2011). Here, we were able to distinguish between these two possibilities using the 343 
DelTel model combined with our Ascl2 transgene, a model which more closely 344 
recapitulates sporadic BWS associated with loss of ICR2-regulated genes. The 345 
absence of fetal overgrowth after combined loss of Cdkn1c and Phlda2 supports our 346 
first scenario whereby the severe placental defects as a consequence of loss of 347 
Cdkn1c prevent late fetal overgrowth. Consistent with this, DelTel7BAC placentae 348 
were substantially heavier and possessed a diminished Jz, with significantly elevated 349 
expression of the SynT-II markers Gcm1 and Synb at E18.5.  350 
In mice, Cdkn1c is fully silenced by layers of epigenetic marks including direct 351 
DNA methylation (John and Lefebvre, 2011). However, in humans the locus lacks 352 
local DNA methylation on the paternal allele (Diaz-Meyer et al., 2005) and there is 353 
“leaky” expression from the paternal CDKN1C allele (Diaz-Meyer et al., 2005; 354 
Hatada et al., 1996; Matsuoka et al., 1996; Taniguchi et al., 1997). This suggests 355 
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that late fetal overgrowth observed in BWS might be attributable to this incomplete 356 
silencing of the paternal CDKN1C allele in humans, which may be sufficient to 357 
prevent the marked placental defect. 358 
There are alternative explanations that must be considered, not in the least 359 
that the mouse and human placenta differ substantially both structurally and 360 
transcriptionally (Carter, 2018; Soncin et al., 2018), which may prevent the accurate 361 
modelling of this disorder in mice. The DelTel7 truncation itself may cause fetal 362 
growth restriction as it includes haploinsufficiency of approximately 20 biallelically 363 
expressed genes located at the telomeric end of distal chromosome 7 (Oh et al., 364 
2008). Arguing against this is the absence of any phenotype associated with paternal 365 
inheritance of the DelTel7 allele, in which appropriate expression of the IC1 and IC2 366 
domain genes is maintained, while one copy of the non-imprinted telomeric genes is 367 
deleted (Oh et al., 2008). A final possibility is that the combination of the Ascl2 368 
transgene plus DelTel7 impairs fetal growth. Evidence against this is provided by the 369 
data showing no growth restriction when the transgene was combined with loss of 370 
function of Cdkn1c in isolation. 371 
 In summary, we successfully used an Ascl2 BAC transgene to rescue 372 
embryonic lethality associated with maternal inheritance of a truncation allele of 373 
distal chromosome 7, thus creating a novel mechanistic model of sporadic BWS. 374 
Whilst our model recapitulated the placentomegaly associated with BWS, we did not 375 
observe fetal overgrowth. Taken together with all the data in this locus in human and 376 
mice, we conclude that it may not be possible to accurately model BWS associated 377 
with loss of imprinting at IC2 in mice due either to differences in the epigenetic 378 
regulation of the domain between mice and human and/or functional differences 379 
between mouse and human placenta. 380 
 381 
Materials and Methods 382 
Mice 383 
All animal studies and breeding were approved by the Universities of Cardiff ethical 384 
committee and performed under a UK Home Office project license (RMJ). Mice were 385 
housed in a conventional unit on a 12-h light–dark cycle with lights coming on at 386 
06.00h with a temperature range of 21°C ± 2 with free access to tap water and 387 
standard chow. The DelTel7 strain was generated as described previously (Oh et al., 388 
2008) and was a kind gift from Louis Lefebvre. The Ascl2BAC, Cdkn1ctm1Sje and 389 
Phlda2loxP targeted alleles were generated as described previously (Frank et al., 390 
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2002; Reed et al., 2012; Zhang et al., 1997). The DelTel7 strain was maintained on 391 
the CD1 background by paternal transmission of the deletion allele. The Cdkn1c and 392 
Phlda2 null lines were maintained on the 129S2/SvHsd (129) background by 393 
paternal transmission of the targeted allele. The Ascl2BAC line was backcrossed by 394 
paternal transmission of the transgene to the 129 background for >8 generations 395 
prior to mating with females of the DelTel7 strain. The Ascl2BAC line was 396 
subsequently backcrossed for >6 generations on to the CD1 background prior to 397 
mating with females of the Cdkn1c and Phlda2 null lines on the 129S2/SvHsd (129) 398 
background. 399 
 400 
Weighing studies 401 
Embryonic and placental wet weights were taken at the stated time points after a 402 
discernible plug. Embryos and placentae were dissected free from extraembryonic 403 
membranes, immersed in ice cold fixative, briefly dried and weighed. 404 
 405 
Histological analyses 406 
Placentas were fixed overnight in phosphate-buffered 4% paraformaldehyde (PFA), 407 
paraffin-embedded and 7 µm sections cut. Haematoxylin and eosin (H&E) staining, 408 
in situ hybridisation and periodic acid Schiff staining for glycogen were performed as 409 
described previously (Tunster et al., 2010). 410 
 411 
Gene expression analysis 412 
Quantitative PCR of reverse transcribed RNA was performed on n = 4 per genotype, 413 
with litter matched controls (n = 2+2 per litter) as described previously (Tunster et al., 414 
2010).  415 
 416 
Placental glycogen measurement 417 
Glycogen was extracted from whole placenta as described previously, resuspended 418 
in 1 ml of H2O, diluted 1 in 2, and glycogen concentration determined using the 419 
phenol-sulphuric acid method (Lo et al., 1970). 420 
 421 
Statistical analyses 422 
The χ2 test was performed to determine whether the number of conceptuses 423 
observed differed from the expected frequency for each genotype. A one-way 424 
ANOVA in conjunction with the Bonferroni correction was used to compare fetal and 425 
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placental weights and placental glycogen content between genotypes. Statistical 426 
significance for analysis of gene expression was determined using the Student's t-427 
Test (two tailed distribution and two sample unequal variance) (Schmittgen and 428 
Livak, 2008). 429 
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Tables 453 
E14.5 
 
WT Ascl2BAC DelTel7BAC 
Observed 61 62 35 
Expected 52.67 52.67 52.67 
% of expected 116% 118% 66% 
χ2 8.90 > 5.991 
E18.5 
 
WT Ascl2BAC DelTel7BAC 
Observed 66 51 30 
Expected 46.67 46.67 46.67 
% of expected 135% 104% 61% 
χ2 13.35 > 5.991 
 454 
Table 1: Restoring Ascl2 gene expression rescues embryonic lethality in 455 
approximately two-thirds of DelTel7 conceptuses. Male Ascl2BAC mice were 456 
mated with female DelTel7 mice to generate 22 litters at E14.5 and 26 litters at 457 
E18.5. DelTelBAC conceptuses were recovered at approximately 60% of the expected 458 
frequency. 459 
 460 
E18.5 Cdkn1c+/- x Ascl2BAC 
 WT Ascl2BAC Cdkn1c-/+ Cdkn1c-/+BAC 
Observed 35 42 46 27 
Expected 37.5 37.5 37.5 37.5 
χ2 5.57 < 7.815 
E18.5 Phlda2+/- x Ascl2BAC 
 WT Ascl2BAC Phlda2-/+ Phlda2-/+BAC 
Observed 54 38 51 44 
Expected 46.75 46.75 46.75 46.75 
χ2 3.31 < 7.815 
 461 
Table 2: Ascl2BAC does not cause embryonic lethality on Cdkn1c or Phlda2 null 462 
backgrounds. Male Ascl2BAC mice were mated with female mice carrying either a 463 
Cdkn1c or Phlda2 targeted allele, generating a total of 46 litters at E18.5. 20 litters 464 
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(150 embryos) were generated from females carrying the Cdkn1c targeted allele and 465 
26 litters (187 embryos) from females carrying the Phlda2 targeted allele. There was 466 
no significant difference between the observed and expected genotype frequency. 467 
  468 
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Figure Legends 650 
Figure 1: Schematic of DelTel7 and Ascl2BAC models. Schematic of mouse distal 651 
chromosome 7 showing the extent of the DelTel7 deletion, which encompasses the 652 
entire IC2 domain and ~20 telomeric genes, whilst leaving the IC1 domain intact. 653 
Imprinting status from (Tunster et al., 2013). 654 
 655 
Figure 2: Restoring Ascl2 gene function rescues DelTel7 lethality. (A) Placental 656 
wet weights at E14.5 and E18.5 for the three viable genotypes generated from 657 
mating Ascl2BAC (129) males with DelTel7 (CD1) females. Ascl2BAC placentae were 658 
not significantly different in weight relative to controls at either stage. DelTel7BAC 659 
placentae were significantly heavier than control littermates at both E14.5 and E18.5. 660 
(B) Corresponding fetal wet weights at E14.5 and E18.5. Although Ascl2BAC fetuses 661 
were slightly heavier than control littermates at E14.5, fetal weight was normalised at 662 
E18.5. In contrast, whilst DelTel7BAC fetuses were no different in weight to controls at 663 
E14.5, they were substantially growth restricted at E18.5. (C) Fetal:placental (F:P) 664 
ratios at E14.5 and E18.5. Placental efficiency was slightly increased for Ascl2BAC at 665 
E14.5 but normalised at E18.5. Efficiency of DelTel7BAC placentae was reduced at 666 
both E14.5 and E18.5. Numerical data is given in Supplementary Table S1. * p < 667 
0.05, *** p < 0.005. 668 
 669 
Figure 3: Disrupted and diminished junctional zone. A and B) Haematoxylin and 670 
Eosin staining of midline placental sections of control (left) and DelTel7BAC (right) 671 
placentae at E14.5 (A) and E18.5 (B). Higher magnification of boxed area shown 672 
below. C and D) Periodic Acid Schiff staining of adjacent sections demonstrating 673 
mislocalisation of GlyT at E14.5 (C) and diminished glycogen staining at E18.5 (D). 674 
Higher magnification of boxed area shown below. E and F) In situ hybridisation with 675 
a probe for the Jz marker Tpbpa further demonstrating the Jz mislocalisation defect 676 
at E14.5 (E) and diminished Jz at E18.5 (F). Higher magnification of boxed area 677 
shown below. 678 
 679 
Figure 4: Transient increase in placental glycogen. (A) Total placental glycogen 680 
of control, Ascl2BAC and DelTel7BAC placentae at E14.5 and E18.5. Total placental 681 
glycogen stores of DelTel7BAC were ~25% greater than controls at E14.5, but 682 
unaltered at E18.5. (B) When normalise by placental weight, DelTel7BAC placental 683 
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glycogen stores expressed as mg glycogen per g of placenta were unaltered. 684 
Numerical data is given in Supplementary Table S2. ** p < 0.01. 685 
 686 
Figure 5: Relative expression levels of key trophoblast lineage markers. (A) 687 
Expression of Junctional zone and SpT markers were similarly reduced at E14.5 and 688 
E18.5, whereas expression of GlyT markers was either slightly elevated or unaltered 689 
at these stages. (B) No consistent alteration in expression of TGC markers was 690 
observed, with Prl3b1 and Prl2c reduced at E14.5 but not at E18.5, whilst expression 691 
of Hand1 and Ctsq was not significantly altered at either stage. (C) Flk1, which is 692 
predominantly expressed in the fetal vasculature of the labyrinth, was reduced at 693 
E14.5 but unaltered at E18.5. Expression of Dlx3, which is widely expressed in the 694 
labyrinth, was unaltered at both stages. Expression of Syna and Ly6e, which are 695 
both expressed in SynT-I, were unaltered at E14.5, with Syna was elevated ~80% at 696 
E18.5, although Ly6e remained unaltered at this stage. (D) Expression of the SynT-II 697 
markers Gcm1 and Synb was unaltered at E14.5, but dramatically increased at 698 
E18.5, with Gcm1 elevated ~10-fold and Synb elevated ~4-fold. N = 4 v 4 from at 699 
least 2 litters. Numerical data is given in Supplementary Table S3. * p < 0.05, ** p < 700 
0.01, *** p < 0.005. 701 
 702 
Figure 6: Excluding a contribution of elevated Ascl2. To exclude a contribution of 703 
elevated Ascl2 in the observed phenotypes we investigated the phenotypic 704 
outcomes associated with Ascl2BAC combined with loss of function of either Phlda2 705 
or Cdkn1c in isolation at E18.5. Placental weights from matings between Ascl2BAC 706 
males and females carrying either a Phlda2 (A) or Cdkn1c (B) loss of function allele. 707 
Consistent with previous reports, both Phlda2-/+ and Cdkn1c-/+ placentae were 708 
substantially heavier than control littermates. Elevated expression of Ascl2BAC did not 709 
affect placental overgrowth of Cdkn1c-/+, with Phlda2-/+BAC placentae significantly 710 
heavier than both control and Phlda2-/+. (C) Phlda2-/+ and Phlda2-/+BAC fetuses did not 711 
differ in weight compared to control littermates, although Phlda2-/+BAC fetuses were 712 
slightly lighter than Phlda2-/+. (D) Cdkn1c-/+ and Cdkn1c-/+BAC fetuses were 713 
substantially heavier than control littermates, with no significant difference in fetal 714 
weight between Cdkn1c-/+ and Cdkn1c-/+BAC. (E, F) The substantial placentomegaly 715 
coupled with the absence of any negative effect on fetal growth resulted in 716 
substantially diminished measures of placental efficiency (F:P ratio) for all genotypes 717 
except Ascl2BAC. For A, C, E; n = WT: 54, Ascl2BAC: 38, Phlda2-/+: 51, Phlda2-/+BAC: 718 
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44; For B, D, F; n = WT: 35, Ascl2BAC: 42, Cdkn1c-/+: 46, Cdkn1c-/+BAC: 27. For G; n = 719 
WT: 47, Ascl2BAC: 29, Phlda2-/+: 36, Phlda2-/+BAC: 32; For H; n = WT: 40, Ascl2BAC: 720 
44, Cdkn1c-/+: 38, Cdkn1c-/+BAC: 22. For I, J, K, L, n = 4 v 4 from at least 2 litters. 721 
Numerical data is given in Supplementary Table S4. NS p > 0.05, * p < 0.05, ** p < 722 
0.01, *** p < 0.005. 723 
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